follitropin beta

Trade name: Follistim

Recombinant proteinapproved

Approved

Sep 29, 1997

Gonadotropin preparations are drugs that mimic the physiological effects of gonadotropins, used therapeutically mainly as fertility medication for ovarian hyperstimulation and ovulation induction. For example, the so-called menotropins consist of LH and FSH extracted from human urine from menopausal women. There are also recombinant variants. — Wikipedia

Clinical trial activity

25 trials · 19 clinical orgs · 1 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
7
Phase 4
9

Earliest trial started Jul 1, 2001 (NCT00702806)

Timeline

1990s

  1. Sep 29, 1997

    Organon — Earliest FDA Approval

  2. Sep 29, 1997

    Organon — NDA Secondary Org

  3. Sep 29, 1997

    Organon — NDA Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedSep 29, 1997

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Availability
Discontinued
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • follistim
  • follistim
  • follistim
  • follistim
  • follitrophin beta
  • follitropin beta
  • follitropin beta
  • follitropin beta
  • follitropin beta
  • follitropin beta
  • follitropin beta
  • follitropin-beta
  • follitropin-beta
  • fsh-b
  • fsh-beta
  • puregon
  • puregon
  • recombinant human follicle stimulating hormone beta

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07285629Early Phase 1 (Phase 1)Dec 6, 2025Minicircle
NCT06193135N/AMar 1, 2024University of Valencia
NCT06175832Phase 4Jan 1, 2024Ghent University
NCT05330130Phase 1Aug 1, 2022ART Fertility Clinics LLC, Organon
NCT04695483Phase 4Mar 7, 2021Vita-Salute University of Milano. Italy
NCT03300518N/ANov 15, 2017Central South University, Merck
NCT03228680Phase 3Jul 29, 2017Ferring
NCT02430740Phase 4Jan 1, 2016Université catholique de Louvain
NCT02635607N/AJan 1, 2016Chongqing Medical University, Chong Qing Reproducive and Genetic Institute, Merck
NCT02471677Phase 4Sep 1, 2015Eugonia
NCT02466204Phase 4Jun 1, 2015Merck, Vietnam National University
NCT01992731Phase 4Dec 31, 2014Free University of Brussels
NCT02309671Phase 2Dec 1, 2014Ferring
NCT01599494Phase 3Mar 1, 2014Merck
NCT01882166N/AOct 1, 2013Norwegian University of Science and Technology
NCT01146418Phase 3Jun 1, 2010Merck
NCT01144416Phase 3Jun 1, 2010Merck
NCT00805935Phase 4Jan 1, 2009Ferring
NCT00802360Phase 4Dec 1, 2008Ferring
NCT00702845Phase 3Dec 1, 2006Merck
Showing 20 of 25 trials
Page 1 / 2

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit10742001
FerringFor profit4432008
ART Fertility Clinics LLCAcademic/Hospital1112022
Central South UniversityAcademic/Hospital1112017
Chongqing Medical UniversityAcademic/Hospital1012016
Chong Qing Reproducive and Genetic InstituteAcademic/Hospital1112016
EugoniaAcademic/Hospital1112015
Free University of BrusselsAcademic/Hospital1112014
Ghent UniversityAcademic/Hospital1112024
Merck KGaAFor profit1112003
Merck SeronoFor profit1012003
MinicircleFor profit1112025
Norwegian University of Science and TechnologyAcademic/Hospital1112013
OrganonFor profit1012022
Université catholique de LouvainAcademic/Hospital1112016
University of PennsylvaniaAcademic/Hospital1112005
University of ValenciaAcademic/Hospital1112024
Vietnam National UniversityAcademic/Hospital1112015
Vita-Salute University of Milano. ItalyAcademic/Hospital1112021
19 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
OrganonFor profitNDA2Sep 29, 1997
OrganonFor profitNDASep 29, 1997